Terminal
Stocks
Spotlight
Research

Stocks
Healthcare
NASDAQ
IKT

Market Cap: $308.96M

II

Inhibikase Therapeutics, Inc.

IKT

NASDAQUSD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive Patents Earnings Surprise

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Financials

Profitability

Gross Profit Margin0.00%

EBITDA Margin0.00%

EBIT Margin0.00%

Pre-tax Margin0.00%

Net Profit Margin0.00%

Earnings Yield-14.84%

Valuation Multiples

Price / Book2.66

Price / Sales0.00

Price / Earnings-4.93

PEG-0.04

Forward PEG-0.79

EV / Sales0.00

EV / EBITDA-4.46

EV / Operating Cash Flow-6.52

EV / Free Cash Flow-6.45

Price / Free Cash Flow-7.17

Price / Operating Cash Flow-9.59

Cash Flow & Capital

Free Cash Flow / Share-$0.25

Operating Cash Flow / Share-$0.24

Free Cash Flow Yield-13.94%

Capex / Revenue0.00%

Capex / Operating Cash Flow-1.06%

Capex / Depreciation19.08

Stock Compensation / Revenue0.00%

Dividend Payout Ratio0.00%

Dividend Yield0.00%

Liquidity & Leverage

Current Ratio15.82

Quick Ratio15.82

Cash Ratio3.04

Debt / Assets0.00

Debt / Capital0.00

Debt / Equity0.00

Long-Term Debt / Capital0.00

Debt / Market Cap0.00%

Net Debt / EBITDA0.50

Solvency Ratio-5.91

Financial Leverage1.07

Efficiency & Working Capital

Asset Turnover0.00

Fixed Asset Turnover0.00

Inventory Turnover0.00

Receivables Turnover0.00

Payables Turnover0.00

Days Sales Outstanding0

Days Inventory Outstanding0

Days Payables Outstanding0

Operating Cycle0

Cash Conversion Cycle0

Working Capital Turnover0.00

Returns & Quality

Return on Equity-42.80%

Return on Assets-37.07%

Return on Invested Capital-42.92%

ROCE-42.92%

Return on Tangible Assets-37.07%

Operating Return on Assets-39.07%

Income Quality0.70

Tax Burden1.00

Interest Burden0.97

Balance Sheet & Intrinsic Metrics

Enterprise Value$277.75M

Invested Capital$152.08M

Working Capital$152.08M

Tangible Asset Value$153.33M

Net Current Asset Value$152.08M

Graham Net-Net$0.85

Book Value / Share$0.88

Tangible Book Value / Share$0.88

Cash / Share$0.91

Financial Health Scores

Piotroski Score2

Altman Z-Score16.32

Revenue$0

EBIT$-62.37M

Market Cap$307.64M

Working Capital$152.08M

Retained Earnings$-178.65M

Total Assets$163.59M

Total Liabilities$10.26M